Skip to main navigation Skip to search Skip to main content

High incidence of candidaemia in a nationwide cohort: Underlying diseases, risk factors and mortality

  • K. R. Lausch*
  • , M. Søgaard
  • , F. S. Rosenvinge
  • , H. K. Johansen
  • , T. Boysen
  • , B. Røder
  • , K. L. Mortensen
  • , L. Nielsen
  • , L. Lemming
  • , B. Olesen
  • , C. Leitz
  • , L. Kristensen
  • , E. Dzajic
  • , L. Østergaard
  • , H. C. Schønheyder
  • , M. C. Arendrup
  • *Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Denmark has a high incidence rate of candidaemia. A Nordic study suggested a higher Danish prevalence of haematological malignancies as an underlying reason. This nationwide study ascertained clinical characteristics of Danish candidaemia patients and investigated potential factors contributing to the high incidence and mortality. Methods: Microbiological and clinical data for candidaemia patients in 2010-2011 were retrieved. 30-day mortality was estimated by hazard ratios (HR) with 95% confidence intervals (CI, Cox regression). Results: Data were available for 912/973 candidaemia episodes (93.7%). Intensive care unit (ICU) held the largest share of patients (43.2%). Prevalent host factors were multi-morbidity (≥2 underlying diseases, 74.2%) and gastrointestinal disease (52.5%). Haematological disease was infrequent (7.8%). Risk factors included antibiotic exposure (90.5%), CVC (71.9%) and Candida colonisation (66.7%). 30-day mortality was 43.4%, and 53.6% in ICU. Mortality was lower for patients with recent abdominal surgery (HR 0.70, 95% CI: 0.54-0.92). Conclusion: A substantial prevalence of multi-morbidity and a high 30-day mortality was found. We hypothesise, that an increasing population of severely ill patients with prolonged supportive treatment and microbiological testing may in part explain the high candidaemia incidence in Denmark. Nationwide studies are warranted to clarify this issue.

Original languageEnglish
Pages (from-to)58-63
Number of pages6
JournalInternational Journal of Infectious Diseases
Volume76
DOIs
Publication statusPublished - Nov 2018

Funding

Dr. Lausch et al. reports grants from Amplyx , Basilea , Cidara , F2G , Gilead , personal fees from Astellas , Basilea, Gilead, MSD , Pfizer , T2Biosystems , grants from Pfizer, personal fees from Astra Zeneca , personal fees from Horizon Pharmaceuticals , personal fees from MSD, Pfizer, personal fees from MSD, grants and personal fees from Gilead, outside the submitted work.

Keywords

  • Candida
  • Candidaemia
  • Epidemiology
  • Mortality
  • Outcome

Fingerprint

Explore the research areas of 'High incidence of candidaemia in a nationwide cohort: Underlying diseases, risk factors and mortality'.

Cite this